Alligator Bioscience AB (publ) Interim report January-March 2020
Stronger focus on clinical projects"The focusing of our operations protects the company’s liquidity, but is also part of our long-term strategy with a emphasis on clinical projects and innovation,” CEO Per Norlén comments.Significant events January-March• Andreas Johannesson was appointed interim CFO.• The COVID-19 pandemic impacts the recruitment of new patients to the company’s ongoing Phase clinical I studies with the ATOR-1015 and ATOR-1017 drug candidates.Events after the end of the period• Decision on stronger focus on the clinical development portfolio aimed at securing